Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Oxurion NV Major Shareholding Notification 2024

Oct 14, 2024

3987_mrq_2024-10-14_76ec62b6-b0c0-4f47-bea7-7558d3c0394b.pdf

Major Shareholding Notification

Open in viewer

Opens in your device viewer

PRESS RELEASE

Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC

Leuven, BELGIUM – October 14, 2024 – 06:00 PM CET - Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notifications as follows:

Oxurion received a transparency notification on October 11, 2024, from Atlas Special Opportunities, LLC indicating that as of October 8, 2024, it held 500,204 shares of the then outstanding 2,002,550 shares, and therefore crossed above the threshold (20%) by virtue of the purchase of voting securities. See Annex 1.

About Oxurion

Oxurion (Euronext Brussels: OXUR) is engaged in developing next-generation standard of care ophthalmic therapies for the treatment of retinal disease. Oxurion is based in Leuven, Belgium. More information is available at www.oxurion.com.

Important information about forward-looking statements

Certain statements in this press release may be considered "forward-looking". Such forward-looking statements are based on current expectations, and, accordingly, entail and are influenced by various risks and uncertainties. The Company therefore cannot provide any assurance that such forward-looking statements will materialize and does not assume any obligation to update or revise any forward-looking statement, whether as a result of new information, future events, or any other reason. Additional information concerning risks and uncertainties affecting the business and other factors that could cause actual results to differ materially from any forwardlooking statement is contained in the Company's Annual Report. This press release does not constitute an offer or invitation for the sale or purchase of securities or assets of Oxurion in any jurisdiction. No securities of Oxurion may be offered or sold within the United States without registration under the U.S. Securities Act of 1933, as amended, or in compliance with an exemption therefrom, and in accordance with any applicable U.S. state securities laws.

For further information please contact:

Oxurion NV Pascal Ghoson Chief Executive Officer [email protected]

________

  1. Article 14, first paragraph, of the Law of 2 May 2007 on disclosure of major holdings.

ANNEX 1

FSMA
FINANCIAL SERVICES AND
MARKETS AUTHORITY
Transparency notification
Form TR-1 BE
PART I
1) Status of the notification
Final
2) Issuer
Name OXURION
ldentification number 0881-620-924
3) Reason for the notification
Acquisition or disposal of voting securities or voting rights
4) Notification by
A person that notifies alone
5) Persons subject to the notification requirement
Name Address (for legal entities)
Atlas Special Opportunities LLC 2500 Westchester Avenue, Suite 401, Purchase, NY 10577
6) Persons that dispose of voting rights (only to be filled in if art. 7 of the Law applies)
Name Address (for legal entities)
Please continue entering the information in part II concerning the
B
persons referred to in Sections 5 and 6
Part II
7) Date on which the threshold is crossed
08/10/2024 (DD/MM/YYYY)
8) Threshold that is crossed (in %)
20
If the holding has fallen below the lowest threshold, you have the option of not entering any numbers in Section 10
9) Denominator
2,002,550
Please enter the denominator before filling in the data
A) Voting rights Previous notification After the transaction
# of voting rights # of voting rights % of voting rights
Holders of voting rights Linked to securities Not linked to the
securities
Linked to securities Not linked to the
securities
Atlas Special Opportunities LLC 47,363 500,204 24.98%
TOTAL 500,204 0 24.98% 0.00%

B) Equivalent financial instruments After the transaction
Holders of equivalent
financial instruments
Type of financial instrument Expiration date Exercise period or
date
# of voting rights
that may be
acquired if the
instrument is
exercised
% of voting rights Settlement
+
TOTAL 0 0.00%
P The totals will be updated once you have clicked on
TOTAL (A & B) # of voting rights % of voting rights
CALCULATE 500,204 24.98%

11) Full chain of controlled undertakings through which the holding is effectively held, if applicable

12) In case of proxy voting for only one GM

(DD/MM/YYYY)
Holder will cease to hold /
will hold again
voting rights as of
13) Additional information
-- -- -- ---------------------------- --
On 4 October 2024 (with etternet date on 8 October 202,41 stars in Ourino NY, as a reall of whith its stareholing incessed b 50,204 stars ( 2 4.98%,
denominator = 2,002,550).
Done at New York
On 11/10/2024 (DD/MMYYYY)
Name & capacity Patrick Vance, Proxyholder Signed by
Patvick Varree
Signature
-94804789605442E

For security reasons, the unsigned form in xlsx format should be
transmitted to [email protected]. You can do this manually
OR if you have MS Outlook at your disposal via th

In addition, a signed copy in PDE format should also be
transmitted.